Achieve Life Sciences
Achieve Life Sciences is a clinical-stage pharmaceutical company developing cytisinicline as a treatment for nicotine dependence and smoking cessation. The company's lead product candidate, cytisinicline, is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors. Achieve received a Complete Response Letter from the FDA for its NDA in 2026.
Company Info
Sector:Pharmaceuticals / Smoking Cessation / Nicotine Addiction
Headquarters:Seattle, Washington, USA
Founded:2015
Website:achievelifesciences.com/
Upcoming Milestones & Key Dates
TBD
FDA
Resubmission of cytisinicline NDA after CRL
Clinical Development Pipeline
Cytisinicline
Target: Nicotinic acetylcholine receptor partial agonistRecent News
No recent news updates available for this company.
Leadership Team
Andrew D. Goldberg, M.D.
Chief Executive Officer
Dr. Anthony Clarke
Chief Scientific Officer